Coronavirus: Nigeria announces second death from pandemic

Coronavirus: Nigeria announces second death from pandemic

The Nigerian Minister of Health, Dr Osagie Ehanire, on Monday, stated that another Nigerian has died from the coronavirus disease.

He stated this at a press briefing in Abuja, the nation’s capital, on Monday, March 30.

Also, the Lagos State Government discharged five coronavirus patients who have fully recovered from the virus.

Also Read: NCDC to follow up over 6000 contacts to curb spread of coronavirus

The Governor of Lagos, Babajide Sanwo-Olu, made this known via his Twitter handle on Monday.

He tweeted, “I am excited to announce some positive news ahead of our lockdown.

“We have just discharged five formerly positive #COVID19 patients from our Infectious Disease Hospital after treatment and multiple testing by our specialists. Congratulations to the healthcare team and the patients.”

With the recent development, six patients have been discharged in Lagos, the first being the Italian that brought coronavirus to Nigeria.

These newly discharged patients bring the total number of people that recovered from the global pandemic to eight.

In another development, the National Agency for Food and Drug Administration and Control (NAFDAC) has ordered for the manufacturing of the anti-malarial drug; Chloroquine for emergency stock for possible clinical treatment of COVID-19 patients.

The Director-General of NAFDAC, Prof. Mojisola  Adeyeye, said in a statement on Monday that the agency had approached a local manufacturing pharmaceutical company; May and Baker to produce the drug.

Adeyeye said that the company, which flagship product was Chloroquine in the past; had produced a batch of the drug for emergency stock for the treatment of COVID-19.

She said Lagos State would start a clinical trial on the drug; to evaluate the its effectiveness.


About The Author

A writer with a keen interest in human stories and topical issues around the world. [email protected]

Related posts

Leave a Reply

Your email address will not be published.